Stock Ratings / Health Care / AZN / earnings

NVS (66) MRK (75) ABT (76) NVO (57) ⌘ Pro Terminal →

AstraZeneca PLC (AZN) Next Earnings Date & Expected ±4.3% Move

$174.40 +2.89% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

AstraZeneca PLC (AZN) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $270.45B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AZN)Realized 20D OHLCV Swing Band: ±4.3%

NEXT EST. WINDOW: Upcoming Quarter (~28 DAYS)

Historical OHLCV Volatility ±4.3% Swing Band

±$7.50 Expected Swing

MODEL EARNINGS SETUP GAUGE

AZN Quantitative Pre-Earnings Setup: 62/100

Trailing EPS: $5.31 • YoY Revenue Growth: 22%

Model Bullish Setup (62/100)Model Risk Weight (38/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating AZN & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on AZN
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AZN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.94%▲ RESISTANCE BREAKOUT

2026-11-01O $169.5H $174.4L $169.5C $174.4VOL 3.72M

RES: $165.0SUP: $154.2SMA50: $164.7SMA200: $180.1

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AZN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AZN Butterfly Map → + Track AZN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. +22.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AZN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AZN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AZN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AZN)

Health Care Rank #103 of 188 ⚔️ NVS vs AZN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AZN vs. NVS, MRK, ABT, NVO)

Industry: Biotechnology: Pharmaceutical Preparations (64 Tracked Issuers)

Across 188 tracked Health Care securities in the Roarable RQD universe, AstraZeneca PLC (AZN) ranks #103 by composite RQD confidence (62/100, grade C) and #8 by equity capitalization ($270.45B). Within this direct 5-issuer industry benchmark cohort, MRK leads on earnings valuation at 19.8x trailing P/E, while MRK leads on capital efficiency and profitability with 20.7% ROIC and 74.8% gross margin. ABT currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with AZN at 62/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AZN ACTIVE AstraZeneca PLC	C	62/100	32.8x	—	9.9%	+2.89%	$270.45B	Benchmark Subject
NVS Novartis AG	C+	66/100	32.8x	—	9.9%	+3.22%	$307.40B	/nvs-vs-azn →
MRK Merck & Company Inc.	B	75/100	19.8x	74.8%	20.7%	+3.83%	$361.02B	/mrk-vs-azn →
ABT Abbott Laboratories	B+	76/100	27.7x	56.4%	11.9%	+1.88%	$180.95B	/abt-vs-azn →
NVO Novo Nordisk A/S	D+	57/100	32.8x	—	9.9%	+2.22%	$173.31B	/nvo-vs-azn →

2. AZN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

AstraZeneca PLC (AZN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $270.45B, trailing P/E of 32.8x, forward P/E of 27.6x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. AZN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, AstraZeneca PLC (NYSE: AZN) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $174.40 (+2.89% 1D, market cap $270.45B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 188 tracked Health Care issuers, AZN ranks #103 in composite RQD confidence.

How does AZN compare to NVS and MRK in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AZN carries a Roarable C (62/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, NVS (Novartis AG) holds a C+ grade (66/100 RQD, P/E 32.8x, ROIC 9.9%, cap $307.40B) and MRK (Merck & Company Inc.) posts a B grade (75/100 RQD, P/E 19.8x, ROIC 20.7%, cap $361.02B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while MRK leads on capital efficiency (20.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AZN?

For AstraZeneca PLC (AZN), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #103 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AZN trading relative to its 50-day, 200-day, and 52-week technical levels?

AZN last traded at $174.40 (+2.89% on volume of 3,715,620 shares), positioning the stock +5.92% above its 50-day simple moving average ($164.65) and -3.16% below its 200-day simple moving average ($180.09). Across its 52-week range of $153.41 to $212.71, AZN sits at the 35.4% percentile with a 14-day RSI of 56.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.3% ($166.90 to $181.90).